Dangerous Beauty
Cell biologist and engineer Matthew Kutys, PhD, and his team harness organoids – living tissues derived from patient tumors – to study how cancer spreads.
University of California San Francisco
Give to UCSFCell biologist and engineer Matthew Kutys, PhD, and his team harness organoids – living tissues derived from patient tumors – to study how cancer spreads.
Fortified stem cells. Enhanced memory. A longevity hormone. UCSF researchers are finding out whether we can cancel – or at least delay – old age.
A new collaborative approach has begun revealing, in detail, how a set of around 100 autism spectrum disorder genes may lead to serious developmental problems. The technique involves looking beyond genes and their mutations, to the proteins they code for.
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.
Thirty-two UCSF scientists are among the most influential individuals in their respective fields, according to the most recent analysis of research citations by the science and intellectual property company, Clarivate.
A previously unknown signaling cycle stemming from our sense of taste helps suppress our appetites.
Researchers offer a theory for why many people experience headaches as soon as 30 minutes after drinking red wine.
A gene expression test can accurately predict the best treatment for meningioma patients by measuring the aggressiveness of their tumors and adjusting treatment accordingly.
A collaboration is between two biomedical researchers bridges the laboratory and clinic to advance the science of itch, allergy and asthma.
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
Scientists found that the nervous system tamps down allergic response, which could change how asthma, Crohn’s and other inflammatory diseases are treated.
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
Scientist proved for the first time that kidney cells, housed in an implantable device functioning as an artificial kidney, can survive inside the body of an animal.
A brain implant and digital avatar allow a paralyzed stroke survivor to speak with for first time in 18 years with the help of artificial intelligence.
Gal-3C, a galectin-3 inhibitor, shows promise in limiting post-MI scarring, improving cardiac function, and outperforming current therapies.
A newly identified platelet factor 4 (PF4) was found to help rejuvenate the old brain and boost the young brain, potentially opening the door to new therapies that aim to restore brain function
A new digital headset designed to measure alterations in brain function could change decisions about how quickly an athlete is ready to return to play after a concussion.
An experimental blood test that reflects injury to nerve cells from multiple sclerosis (MS) was found to work for children with MS and other neurological conditions, even when they are symptom-free.